Smokefree Innotec Inc. (SFIO)
Smoking causes increased stomach acid secretion, leading to heartburn and ulcers. Smokers have higher rates of deadly pancreatic cancer. Many of the carcinogens from cigarettes are excreted in the urine where their presence can cause bladder cancer, which is often fatal. Tobacco smoke can also cause gum disease, tooth decay and bad breath. The teeth become unsightly and yellow. Smokers may experience frequent headaches.
Electronic cigarette exhalation leaves a nice and pleasant aroma that quickly turns odorless upon dispersing into the air. Electronic cigarettes do not stain your teeth yellow and leave you with a serious case of disgusting smoker’s breath. Electronic cigarettes are not heavy or bulky and you only have to carry one.
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free. Smokefree Innotec Inc’s products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking tobacco or similar substances is prohibited.However Smokefree Innotec, Inc products are not intended for any prevention or therapeutic treatment of any disease.
According to recent information from SFIO’s marketing representatives in Australia, they are being successful in securing meetings with the largest distributors in Australia and New Zealand intending to finalizing orders, including one comparable to the size of Conway of Germany, SFIO’s European retailer with over 120,000 outlets. They report their first response from the Australians is that they like the product and consider it very favorable for their purposes. Smokefree, while complying with regional regulations, expects to develop and eventually acquire sizable orders from these sources. Internet advertising and marketing continues development and testing, and will undergo a formal launch soon with search engine optimization. Readers are invited to go to the SFIO website and visit the shopping cart page that has been added, with Smokefree’s REAL nicotine products to be added as soon as supplies now on the way are on hand to commence taking orders.
For more information about Smokefree Innotec, Inc. visit its website www.smokefree-innotec.com
DARA BioSciences, Inc. (DARA)
Diabetes is caused by a lack of insulin, which in turn causes excess sugar to accumulate in the blood. There are two types of diabetes; Type 1, also called childhood diabetes, is where the pancreas does not make any insulin at all, and insulin must be administered in order to keep blood sugar at more normal levels. Type 2, or adult-onset diabetes, is where the pancreas does make some insulin, but the body does not utilize it properly, and thus, the blood sugar escalates.
Both types must be controlled by diet, medication and lifestyle changes. Otherwise, severe complications may set in if blood sugars are allowed to go unchecked over a long period of time. Therefore, while diabetes is not caused by a germ or a virus, it is still considered a disase, and a very serious one if not taken care of properly. Complications from this disease include blindness, kidney failure, nerve damage, amputations of the feet and lower limbs, and heart disease.
DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage Biopharmaceutical Company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. The company continues to build a diverse pipeline, including candidates for the treatment of metabolic diseases (diabetes), and pain.
DARA BioSciences, Inc.’s shares are publicly traded on the NASDAQ under the ticker symbol DARA.
DARA BioSciences, Inc. recently announced that the Company will present at three financial conference during May, 2011. Conference information is provided below:
Taglich Brothers - 8th Annual Small Cap Equity Conference
New York City, NY - May 3, 2011
MDB Capital Group - Bright Lights Conference
New York City, NY - May 10-11, 2011
Noble Financial Capital Markets — Seventh Annual Equity Conference
Hollywood, FL — May 16-17, 2011
Conference attendees may arrange one-on-one meetings with DARA through the respective conference sponsors.
Interested parties can access a live web cast of the presentations at www.darabiosciences.com under the Investor Relations section. A replay of the presentation will be available at the same location.
For more information about DARA please visit http://www.darabiosciences.com
Interphase Corp. (Nasdaq:INPH) a leading global provider of solutions for converged communications networks, is scheduled to announced its First Quarter 2011 results on Thursday, April 28, 2011 after market close. A conference call is scheduled for Thursday, April 28, 2011 at 4:30 p.m. CT to discuss the results.
Interphase Corporation and its subsidiaries provide building blocks, integrated subsystems, and gateway appliances in the areas of network connectivity, content management, and packet processing solutions in the converged communications network.
AngioDynamics Inc. (Nasdaq:ANGO) a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, reported financial results for the fiscal 2011 third quarter ended February 28, 2011. Net sales in the third quarter were $54.6 million, a 5% increase over the $52.2 million reported in the prior year period. Oncology/Surgery sales increased 19% to $16.3 million from the prior year, and included $1.9 million in NanoKnife� System sales, up from $800,000 in the prior year quarter. Vascular sales were $38.3 million, virtually identical to the third quarter a year ago. International sales in the third quarter increased 8% (9% in constant currency) to $6.3 million from the prior year period.
AngioDynamics, Inc. designs, develops, manufactures, and markets various therapeutic and diagnostic devices that enable interventional physicians to treat peripheral vascular disease, tumors, and other non-coronary diseases.
Lincoln Educational Services Corporation (Nasdaq:LINC) announced that it will host a conference call to discuss results for its first quarter on Thursday, May 5, 2011 at 11:00 a.m. Eastern time. A news release outlining Lincoln’s results will be issued before 9:30 a.m. Eastern time on that day. To access the live webcast of the conference call, please go to the investor relations section of Lincoln’s website at http://www.lincolnedu.com. Participants can also listen to the conference call by dialing 866-825-1709 (domestic) or 617-213-8060 (international) and providing access code 54808682. Please log in or dial into the call at least 10 minutes prior to the start time.
Lincoln Educational Services Corporation provides career-oriented post-secondary education services in the United States. It offers degree and diploma programs for high school graduates and working adults in the areas of health sciences, automotive technology, skilled trades, hospitality services, and business and information technology.
No comments :
Post a Comment